Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 25 entries
Sorted by: Best Match Show Resources per page
Lipoprotein(a) Associated Molecules are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis.

JACC. Basic to translational science

Torzewski M, Ravandi A, Yeang C, Edel A, Bhindi R, Kath S, Twardowski L, Schmid J, Yang X, Franke UFW, Witztum JL, Tsimikas S.
PMID: 29147686
JACC Basic Transl Sci. 2017 Jun;2(3):229-240. doi: 10.1016/j.jacbts.2017.02.004. Epub 2017 Jun 26.

The

Cite
Torzewski M, Ravandi A, Yeang C, et al. Lipoprotein(a) Associated Molecules are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis. JACC Basic Transl Sci. 2017;2(3):229-240doi: 10.1016/j.jacbts.2017.02.004.
Torzewski, M., Ravandi, A., Yeang, C., Edel, A., Bhindi, R., Kath, S., Twardowski, L., Schmid, J., Yang, X., Franke, U. F. W., Witztum, J. L., & Tsimikas, S. (2017). Lipoprotein(a) Associated Molecules are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis. JACC. Basic to translational science, 2(3), 229-240. https://doi.org/10.1016/j.jacbts.2017.02.004
Torzewski, Michael, et al. "Lipoprotein(a) Associated Molecules are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis." JACC. Basic to translational science vol. 2,3 (2017): 229-240. doi: https://doi.org/10.1016/j.jacbts.2017.02.004
Torzewski M, Ravandi A, Yeang C, Edel A, Bhindi R, Kath S, Twardowski L, Schmid J, Yang X, Franke UFW, Witztum JL, Tsimikas S. Lipoprotein(a) Associated Molecules are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis. JACC Basic Transl Sci. 2017 Jun;2(3):229-240. doi: 10.1016/j.jacbts.2017.02.004. Epub 2017 Jun 26. PMID: 29147686; PMCID: PMC5685511.
Copy Download .nbib Format: NLM
Publisher Correction: Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice.

Nature

Que X, Hung MY, Yeang C, Gonen A, Prohaska TA, Sun X, Diehl C, Määttä A, Gaddis DE, Bowden K, Pattison J, MacDonald JG, Ylä-Herttuala S, Mellon PL, Hedrick CC, Ley K, Miller YI, Glass CK, Peterson KL, Binder CJ, Tsimikas S, Witztum JL.
PMID: 30013121
Nature. 2018 Sep;561(7724):E43. doi: 10.1038/s41586-018-0313-x.

In this Letter, affiliation number 1 was originally missing from the HTML; the affiliations were missing for author Ming-Yow Hung in the HTML; and the Fig. 4 legend erroneously referred to panels a-h, instead of a-g. These errors have...

Cite
Que X, Hung MY, Yeang C, et al. Publisher Correction: Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature. 2018;561(7724):E43doi: 10.1038/s41586-018-0313-x.
Que, X., Hung, M. Y., Yeang, C., Gonen, A., Prohaska, T. A., Sun, X., Diehl, C., Määttä, A., Gaddis, D. E., Bowden, K., Pattison, J., MacDonald, J. G., Ylä-Herttuala, S., Mellon, P. L., Hedrick, C. C., Ley, K., Miller, Y. I., Glass, C. K., Peterson, K. L., Binder, C. J., Tsimikas, S., & Witztum, J. L. (2018). Publisher Correction: Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature, 561(7724), E43. https://doi.org/10.1038/s41586-018-0313-x
Que, Xuchu, et al. "Publisher Correction: Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice." Nature vol. 561,7724 (2018): E43. doi: https://doi.org/10.1038/s41586-018-0313-x
Que X, Hung MY, Yeang C, Gonen A, Prohaska TA, Sun X, Diehl C, Määttä A, Gaddis DE, Bowden K, Pattison J, MacDonald JG, Ylä-Herttuala S, Mellon PL, Hedrick CC, Ley K, Miller YI, Glass CK, Peterson KL, Binder CJ, Tsimikas S, Witztum JL. Publisher Correction: Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature. 2018 Sep;561(7724):E43. doi: 10.1038/s41586-018-0313-x. PMID: 30013121.
Copy Download .nbib Format: NLM
Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles.

Journal of the Endocrine Society

O'Dea LSL, MacDougall J, Alexander VJ, Digenio A, Hubbard B, Arca M, Moriarty PM, Kastelein JJP, Bruckert E, Soran H, Witztum JL, Hegele RA, Gaudet D.
PMID: 31777768
J Endocr Soc. 2019 Oct 11;3(12):2397-2410. doi: 10.1210/js.2019-00214. eCollection 2019 Dec 01.

CONTEXT: Differentiation between familial chylomicronemia syndrome (FCS, type 1 hyperlipoproteinemia), a rare metabolic disorder, and the more common multifactorial severe hypertriglyceridemia (sHTG, type 5 hyperlipoproteinemia) is challenging because of their overlapping symptoms but important in patient management.OBJECTIVE: To assess...

Cite
O'Dea LSL, MacDougall J, Alexander VJ, et al. Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. J Endocr Soc. 2019;3(12):2397-2410doi: 10.1210/js.2019-00214.
O'Dea, L. S. L., MacDougall, J., Alexander, V. J., Digenio, A., Hubbard, B., Arca, M., Moriarty, P. M., Kastelein, J. J. P., Bruckert, E., Soran, H., Witztum, J. L., Hegele, R. A., & Gaudet, D. (2019). Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. Journal of the Endocrine Society, 3(12), 2397-2410. https://doi.org/10.1210/js.2019-00214
O'Dea, Louis St L, et al. "Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles." Journal of the Endocrine Society vol. 3,12 (2019): 2397-2410. doi: https://doi.org/10.1210/js.2019-00214
O'Dea LSL, MacDougall J, Alexander VJ, Digenio A, Hubbard B, Arca M, Moriarty PM, Kastelein JJP, Bruckert E, Soran H, Witztum JL, Hegele RA, Gaudet D. Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. J Endocr Soc. 2019 Oct 11;3(12):2397-2410. doi: 10.1210/js.2019-00214. eCollection 2019 Dec 01. PMID: 31777768; PMCID: PMC6864364.
Copy Download .nbib Format: NLM
Traumatic Bereavements: Rebalancing the Relationship to the Deceased and the Death Story Using the Two-Track Model of Bereavement.

Frontiers in psychiatry

Rubin SS, Malkinson R, Witztum E.
PMID: 33093833
Front Psychiatry. 2020 Sep 15;11:537596. doi: 10.3389/fpsyt.2020.537596. eCollection 2020.

Bereavements that occur under external traumatic circumstances increase the risk for dysfunction, trauma symptomatology, as well as disordered and prolonged grief. While the majority of individuals who have experienced traumatic bereavements do not meet formal criteria for posttraumatic stress...

Cite
Rubin SS, Malkinson R, Witztum E. Traumatic Bereavements: Rebalancing the Relationship to the Deceased and the Death Story Using the Two-Track Model of Bereavement. Front Psychiatry. 2020;11:537596doi: 10.3389/fpsyt.2020.537596.
Rubin, S. S., Malkinson, R., & Witztum, E. (2020). Traumatic Bereavements: Rebalancing the Relationship to the Deceased and the Death Story Using the Two-Track Model of Bereavement. Frontiers in psychiatry, 11537596. https://doi.org/10.3389/fpsyt.2020.537596
Rubin, Simon Shimshon, et al. "Traumatic Bereavements: Rebalancing the Relationship to the Deceased and the Death Story Using the Two-Track Model of Bereavement." Frontiers in psychiatry vol. 11 (2020): 537596. doi: https://doi.org/10.3389/fpsyt.2020.537596
Rubin SS, Malkinson R, Witztum E. Traumatic Bereavements: Rebalancing the Relationship to the Deceased and the Death Story Using the Two-Track Model of Bereavement. Front Psychiatry. 2020 Sep 15;11:537596. doi: 10.3389/fpsyt.2020.537596. eCollection 2020. PMID: 33093833; PMCID: PMC7523537.
Copy Download .nbib Format: NLM
Oxidized Phospholipids Promote NETosis and Arterial Thrombosis in LNK(SH2B3) Deficiency.

Circulation

Dou H, Kotini A, Liu W, Fidler T, Endo-Umeda K, Sun X, Olszewska M, Xiao T, Abramowicz S, Yalcinkaya M, Hardaway B, Tsimikas S, Que X, Bick A, Emdin C, Natarajan P, Papapetrou EP, Witztum JL, Wang N, Tall AR.
PMID: 34846914
Circulation. 2021 Dec 14;144(24):1940-1954. doi: 10.1161/CIRCULATIONAHA.121.056414. Epub 2021 Nov 30.

CONCLUSIONS: Hematopoietic

Cite
Dou H, Kotini A, Liu W, et al. Oxidized Phospholipids Promote NETosis and Arterial Thrombosis in LNK(SH2B3) Deficiency. Circulation. 2021;144(24):1940-1954doi: 10.1161/CIRCULATIONAHA.121.056414.
Dou, H., Kotini, A., Liu, W., Fidler, T., Endo-Umeda, K., Sun, X., Olszewska, M., Xiao, T., Abramowicz, S., Yalcinkaya, M., Hardaway, B., Tsimikas, S., Que, X., Bick, A., Emdin, C., Natarajan, P., Papapetrou, E. P., Witztum, J. L., Wang, N., & Tall, A. R. (2021). Oxidized Phospholipids Promote NETosis and Arterial Thrombosis in LNK(SH2B3) Deficiency. Circulation, 144(24), 1940-1954. https://doi.org/10.1161/CIRCULATIONAHA.121.056414
Dou, Huijuan, et al. "Oxidized Phospholipids Promote NETosis and Arterial Thrombosis in LNK(SH2B3) Deficiency." Circulation vol. 144,24 (2021): 1940-1954. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.056414
Dou H, Kotini A, Liu W, Fidler T, Endo-Umeda K, Sun X, Olszewska M, Xiao T, Abramowicz S, Yalcinkaya M, Hardaway B, Tsimikas S, Que X, Bick A, Emdin C, Natarajan P, Papapetrou EP, Witztum JL, Wang N, Tall AR. Oxidized Phospholipids Promote NETosis and Arterial Thrombosis in LNK(SH2B3) Deficiency. Circulation. 2021 Dec 14;144(24):1940-1954. doi: 10.1161/CIRCULATIONAHA.121.056414. Epub 2021 Nov 30. PMID: 34846914; PMCID: PMC8663540.
Copy Download .nbib Format: NLM
CD1d Selectively Down Regulates the Expression of the Oxidized Phospholipid-Specific E06 IgM Natural Antibody in .

Antibodies (Basel, Switzerland)

Biswas TK, VanderLaan PA, Que X, Gonen A, Krishack P, Binder CJ, Witztum JL, Getz GS, Reardon CA.
PMID: 32635160
Antibodies (Basel). 2020 Jul 03;9(3). doi: 10.3390/antib9030030.

Natural antibodies (NAbs) are important regulators of tissue homeostasis and inflammation and are thought to have diverse protective roles in a variety of pathological states. E06 is a T15 idiotype IgM NAb exclusively produced by B-1 cells, which recognizes...

Cite
Biswas TK, VanderLaan PA, Que X, et al. CD1d Selectively Down Regulates the Expression of the Oxidized Phospholipid-Specific E06 IgM Natural Antibody in . Antibodies (Basel). 2020;9(3)doi: 10.3390/antib9030030.
Biswas, T. K., VanderLaan, P. A., Que, X., Gonen, A., Krishack, P., Binder, C. J., Witztum, J. L., Getz, G. S., & Reardon, C. A. (2020). CD1d Selectively Down Regulates the Expression of the Oxidized Phospholipid-Specific E06 IgM Natural Antibody in . Antibodies (Basel, Switzerland), 9(3), . https://doi.org/10.3390/antib9030030
Biswas, Tapan K, et al. "CD1d Selectively Down Regulates the Expression of the Oxidized Phospholipid-Specific E06 IgM Natural Antibody in ." Antibodies (Basel, Switzerland) vol. 9,3 (2020). doi: https://doi.org/10.3390/antib9030030
Biswas TK, VanderLaan PA, Que X, Gonen A, Krishack P, Binder CJ, Witztum JL, Getz GS, Reardon CA. CD1d Selectively Down Regulates the Expression of the Oxidized Phospholipid-Specific E06 IgM Natural Antibody in . Antibodies (Basel). 2020 Jul 03;9(3). doi: 10.3390/antib9030030. PMID: 32635160; PMCID: PMC7551411.
Copy Download .nbib Format: NLM
Lipoprotein(a), Oxidized Phospholipids, and Aortic Valve Microcalcification Assessed by 18F-Sodium Fluoride Positron Emission Tomography and Computed Tomography.

CJC open

Després AA, Perrot N, Poulin A, Tastet L, Shen M, Chen HY, Bourgeois R, Trottier M, Tessier M, Guimond J, Nadeau M, Engert JC, Thériault S, Bossé Y, Witztum JL, Couture P, Mathieu P, Dweck MR, Tsimikas S, Thanassoulis G, Pibarot P, Clavel MA, Arsenault BJ.
PMID: 32159096
CJC Open. 2019 Apr 12;1(3):131-140. doi: 10.1016/j.cjco.2019.03.004. eCollection 2019 May.

BACKGROUND: Lipoprotein(a) (Lp[a]) is the preferential lipoprotein carrier of oxidized phospholipids (OxPLs) and a well-established genetic risk factor for calcific aortic valve stenosis (CAVS). Whether Lp(a) predicts aortic valve microcalcification in individuals without CAVS is unknown. Our objective was...

Cite
Després AA, Perrot N, Poulin A, et al. Lipoprotein(a), Oxidized Phospholipids, and Aortic Valve Microcalcification Assessed by 18F-Sodium Fluoride Positron Emission Tomography and Computed Tomography. CJC Open. 2019;1(3):131-140doi: 10.1016/j.cjco.2019.03.004.
Després, A. A., Perrot, N., Poulin, A., Tastet, L., Shen, M., Chen, H. Y., Bourgeois, R., Trottier, M., Tessier, M., Guimond, J., Nadeau, M., Engert, J. C., Thériault, S., Bossé, Y., Witztum, J. L., Couture, P., Mathieu, P., Dweck, M. R., Tsimikas, S., Thanassoulis, G., Pibarot, P., Clavel, M. A., & Arsenault, B. J. (2019). Lipoprotein(a), Oxidized Phospholipids, and Aortic Valve Microcalcification Assessed by 18F-Sodium Fluoride Positron Emission Tomography and Computed Tomography. CJC open, 1(3), 131-140. https://doi.org/10.1016/j.cjco.2019.03.004
Després, Audrey-Anne, et al. "Lipoprotein(a), Oxidized Phospholipids, and Aortic Valve Microcalcification Assessed by 18F-Sodium Fluoride Positron Emission Tomography and Computed Tomography." CJC open vol. 1,3 (2019): 131-140. doi: https://doi.org/10.1016/j.cjco.2019.03.004
Després AA, Perrot N, Poulin A, Tastet L, Shen M, Chen HY, Bourgeois R, Trottier M, Tessier M, Guimond J, Nadeau M, Engert JC, Thériault S, Bossé Y, Witztum JL, Couture P, Mathieu P, Dweck MR, Tsimikas S, Thanassoulis G, Pibarot P, Clavel MA, Arsenault BJ. Lipoprotein(a), Oxidized Phospholipids, and Aortic Valve Microcalcification Assessed by 18F-Sodium Fluoride Positron Emission Tomography and Computed Tomography. CJC Open. 2019 Apr 12;1(3):131-140. doi: 10.1016/j.cjco.2019.03.004. eCollection 2019 May. PMID: 32159096; PMCID: PMC7063623.
Copy Download .nbib Format: NLM
RNA-Targeted Therapeutics.

Cell metabolism

Crooke ST, Witztum JL, Bennett CF, Baker BF.
PMID: 30726759
Cell Metab. 2019 Feb 05;29(2):501. doi: 10.1016/j.cmet.2019.01.001.

No abstract available.

Cite
Crooke ST, Witztum JL, Bennett CF, et al. RNA-Targeted Therapeutics. Cell Metab. 2019;29(2):501doi: 10.1016/j.cmet.2019.01.001.
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2019). RNA-Targeted Therapeutics. Cell metabolism, 29(2), 501. https://doi.org/10.1016/j.cmet.2019.01.001
Crooke, Stanley T, et al. "RNA-Targeted Therapeutics." Cell metabolism vol. 29,2 (2019): 501. doi: https://doi.org/10.1016/j.cmet.2019.01.001
Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-Targeted Therapeutics. Cell Metab. 2019 Feb 05;29(2):501. doi: 10.1016/j.cmet.2019.01.001. PMID: 30726759.
Copy Download .nbib Format: NLM
Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements.

Journal of lipid research

Yeang C, Witztum JL, Tsimikas S.
PMID: 33636163
J Lipid Res. 2021;62:100053. doi: 10.1016/j.jlr.2021.100053. Epub 2021 Feb 24.

Current methods for determining "LDL-C" in clinical practice measure the cholesterol content of both LDL and lipoprotein(a) [Lp(a)-C]. We developed a high-throughput, sensitive, and rapid method to quantitate Lp(a)-C and improve the accuracy of LDL-C by subtracting for Lp(a)-C...

Cite
Yeang C, Witztum JL, Tsimikas S. Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. J Lipid Res. 2021;62:100053doi: 10.1016/j.jlr.2021.100053.
Yeang, C., Witztum, J. L., & Tsimikas, S. (2021). Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. Journal of lipid research, 62100053. https://doi.org/10.1016/j.jlr.2021.100053
Yeang, Calvin, et al. "Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements." Journal of lipid research vol. 62 (2021): 100053. doi: https://doi.org/10.1016/j.jlr.2021.100053
Yeang C, Witztum JL, Tsimikas S. Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. J Lipid Res. 2021;62:100053. doi: 10.1016/j.jlr.2021.100053. Epub 2021 Feb 24. PMID: 33636163; PMCID: PMC8042377.
Copy Download .nbib Format: NLM
Gold nanoparticles in radiation research: potential applications for imaging and radiosensitization.

Translational cancer research

Dorsey JF, Sun L, Joh DY, Witztum A, Kao GD, Alonso-Basanta M, Avery S, Hahn SM, Al Zaki A, Tsourkas A.
PMID: 25429358
Transl Cancer Res. 2013 Aug 01;2(4):280-291. doi: 10.3978/j.issn.2218-676X.2013.08.09.

The potential of gold nanoparticles (GNPs) in therapeutic and diagnostic cancer applications is becoming increasingly recognized. These biologically compatible particles can be easily synthesized, tuned to different sizes, and functionalized by conjugation to various biologically useful materials. Efficient and...

Cite
Dorsey JF, Sun L, Joh DY, et al. Gold nanoparticles in radiation research: potential applications for imaging and radiosensitization. Transl Cancer Res. 2013;2(4):280-291doi: 10.3978/j.issn.2218-676X.2013.08.09.
Dorsey, J. F., Sun, L., Joh, D. Y., Witztum, A., Kao, G. D., Alonso-Basanta, M., Avery, S., Hahn, S. M., Al Zaki, A., & Tsourkas, A. (2013). Gold nanoparticles in radiation research: potential applications for imaging and radiosensitization. Translational cancer research, 2(4), 280-291. https://doi.org/10.3978/j.issn.2218-676X.2013.08.09
Dorsey, Jay F, et al. "Gold nanoparticles in radiation research: potential applications for imaging and radiosensitization." Translational cancer research vol. 2,4 (2013): 280-291. doi: https://doi.org/10.3978/j.issn.2218-676X.2013.08.09
Dorsey JF, Sun L, Joh DY, Witztum A, Kao GD, Alonso-Basanta M, Avery S, Hahn SM, Al Zaki A, Tsourkas A. Gold nanoparticles in radiation research: potential applications for imaging and radiosensitization. Transl Cancer Res. 2013 Aug 01;2(4):280-291. doi: 10.3978/j.issn.2218-676X.2013.08.09. PMID: 25429358; PMCID: PMC4241969.
Copy Download .nbib Format: NLM
Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements.

Journal of lipid research

Yeang C, Witztum JL, Tsimikas S.
PMID: 33636163
J Lipid Res. 2021 Feb 24;62:100053. doi: 10.1016/j.jlr.2021.100053. Epub 2021 Feb 24.

Current methods for determining "LDL-C" in clinical practice measure the cholesterol content of both LDL and lipoprotein(a) [Lp(a)-C]. We developed a high-throughput, sensitive, and rapid method to quantitate Lp(a)-C and improve the accuracy of LDL-C by subtracting for Lp(a)-C...

Cite
Yeang C, Witztum JL, Tsimikas S. Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. J Lipid Res. 2021;62:100053doi: 10.1016/j.jlr.2021.100053.
Yeang, C., Witztum, J. L., & Tsimikas, S. (2021). Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. Journal of lipid research, 62100053. https://doi.org/10.1016/j.jlr.2021.100053
Yeang, Calvin, et al. "Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements." Journal of lipid research vol. 62 (2021): 100053. doi: https://doi.org/10.1016/j.jlr.2021.100053
Yeang C, Witztum JL, Tsimikas S. Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. J Lipid Res. 2021 Feb 24;62:100053. doi: 10.1016/j.jlr.2021.100053. Epub 2021 Feb 24. PMID: 33636163; PMCID: PMC8042377.
Copy Download .nbib Format: NLM
Neutralization of oxidized phospholipids attenuates age-associated bone loss in mice.

Aging cell

Palmieri M, Almeida M, Nookaew I, Gomez-Acevedo H, Joseph TE, Que X, Tsimikas S, Sun X, Manolagas SC, Witztum JL, Ambrogini E.
PMID: 34278710
Aging Cell. 2021 Aug;20(8):e13442. doi: 10.1111/acel.13442. Epub 2021 Jul 19.

Oxidized phospholipids (OxPLs) are pro-inflammatory molecules that affect bone remodeling under physiological conditions. Transgenic expression of a single-chain variable fragment (scFv) of the antigen-binding domain of E06, an IgM natural antibody that recognizes the phosphocholine (PC) moiety of OxPLs,...

Cite
Palmieri M, Almeida M, Nookaew I, et al. Neutralization of oxidized phospholipids attenuates age-associated bone loss in mice. Aging Cell. 2021;20(8):e13442doi: 10.1111/acel.13442.
Palmieri, M., Almeida, M., Nookaew, I., Gomez-Acevedo, H., Joseph, T. E., Que, X., Tsimikas, S., Sun, X., Manolagas, S. C., Witztum, J. L., & Ambrogini, E. (2021). Neutralization of oxidized phospholipids attenuates age-associated bone loss in mice. Aging cell, 20(8), e13442. https://doi.org/10.1111/acel.13442
Palmieri, Michela, et al. "Neutralization of oxidized phospholipids attenuates age-associated bone loss in mice." Aging cell vol. 20,8 (2021): e13442. doi: https://doi.org/10.1111/acel.13442
Palmieri M, Almeida M, Nookaew I, Gomez-Acevedo H, Joseph TE, Que X, Tsimikas S, Sun X, Manolagas SC, Witztum JL, Ambrogini E. Neutralization of oxidized phospholipids attenuates age-associated bone loss in mice. Aging Cell. 2021 Aug;20(8):e13442. doi: 10.1111/acel.13442. Epub 2021 Jul 19. PMID: 34278710; PMCID: PMC8373359.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 25 entries